Mercury Biopharmaceutical (ROCO:6932) Total Liabilities : NT$62.93 Mil (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Mercury Biopharmaceutical Total Liabilities?

Mercury Biopharmaceutical's Total Liabilities for the quarter that ended in Dec. 2024 was NT$62.93 Mil.

Mercury Biopharmaceutical's quarterly Total Liabilities increased from Dec. 2023 (NT$49.72 Mil) to Jun. 2024 (NT$54.90 Mil) and increased from Jun. 2024 (NT$54.90 Mil) to Dec. 2024 (NT$62.93 Mil).

Mercury Biopharmaceutical's annual Total Liabilities increased from Dec. 2022 (NT$49.60 Mil) to Dec. 2023 (NT$49.72 Mil) and increased from Dec. 2023 (NT$49.72 Mil) to Dec. 2024 (NT$62.93 Mil).

Mercury Biopharmaceutical Total Liabilities Historical Data

The historical data trend for Mercury Biopharmaceutical's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mercury Biopharmaceutical Total Liabilities Chart

Mercury Biopharmaceutical Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

0.31

2.93

49.60

49.72

62.93

Mercury Biopharmaceutical Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Liabilities	Get a 7-Day Free Trial					49.60	46.69	49.72	54.90	62.93

Mercury Biopharmaceutical Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Mercury Biopharmaceutical's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	19.236	+	(43.693	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	62.93

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	353.203	-	290.274
	=	62.93

Mercury Biopharmaceutical's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	19.236	+	(43.693	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	62.93

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	353.203	-	290.274
	=	62.93

Mercury Biopharmaceutical Total Liabilities Related Terms

Thank you for viewing the detailed overview of Mercury Biopharmaceutical's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Mercury Biopharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mercury Biopharmaceutical Corp (ROCO:6932) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 653-1, Bannan Road, 15th Floor, Zhonghe District, New Taipei City, TWN

Website

https://www.merdury.com.tw

Mercury Biopharmaceutical Corp focuses on the development of drugs for unmet medical needs. It offers a development platform focusing on rapid release and free adjustable doses. Its 3D powder bonding method (binder jetting) combines powder and special molding adhesive and stacks them in layers.

Mercury Biopharmaceutical Headlines

No Headlines